{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:40:04Z","timestamp":1759974004100,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.medmal.2006.11.003","type":"journal-article","created":{"date-parts":[[2007,1,18]],"date-time":"2007-01-18T07:20:09Z","timestamp":1169104809000},"page":"172-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lopinavir\/ritonavir chez\u00a0le\u00a0patient infect\u00e9 par\u00a0le\u00a0VIH en\u00a0situation d'\u00e9chec virologique prolong\u00e9 : \u00e9volution immunovirologique et\u00a0tol\u00e9rance chez\u00a0121\u00a0patients de\u00a0la\u00a0cohorte ANRS CO8 Aproco-Copilote"],"prefix":"10.1016","volume":"37","author":[{"given":"C.","family":"Brunet-Fran\u00e7ois","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Masquelier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Le Moing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lewden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Dellamonica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Cuzin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Allavena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Spire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Ch\u00eane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Raffi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medmal.2006.11.003_bib1","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa012354","article-title":"Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection","volume":"346","author":"Walmsley","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medmal.2006.11.003_bib2","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1128\/JVI.75.16.7462-7469.2001","article-title":"Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients","volume":"75","author":"Kempf","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.medmal.2006.11.003_bib3","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1128\/AAC.46.9.2926-2932.2002","article-title":"Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients","volume":"46","author":"Masquelier","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.medmal.2006.11.003_bib4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1086\/339014","article-title":"Safety and antiviral activity at 48\u00a0weeks of lopinavir\/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients","volume":"185","author":"Benson","year":"2002","journal-title":"J. Infect. Dis."},{"year":"2001","series-title":"Kaletra (ABT-378\/r) and efavirenz: one-year safety\/efficacy evaluation and phenotypic breakpoints in multiple-PI-experienced patients","author":"Clumeck","key":"10.1016\/j.medmal.2006.11.003_bib5"},{"key":"10.1016\/j.medmal.2006.11.003_bib6","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/00126334-200108010-00007","article-title":"Clinical, biologic and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors","volume":"27","author":"Le Moing","year":"2001","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.medmal.2006.11.003_bib7","doi-asserted-by":"crossref","first-page":"1S31","DOI":"10.1016\/S0755-4982(05)73407-2","article-title":"Devenir des patients infect\u00e9s par le VIH apr\u00e8s cinq ans de traitement antir\u00e9troviral comprenant un IP: exemple de la cohorte Aproco-Copilote","volume":"34","author":"Le Moing","year":"2005","journal-title":"Presse Med."},{"key":"10.1016\/j.medmal.2006.11.003_bib8","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1097\/01.aids.0000131358.29586.6b","article-title":"Evolution of resistance to drugs in HIV-1 infected patients failing antiretroviral therapy","volume":"18","author":"Kantor","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.medmal.2006.11.003_bib9","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1086\/344358","article-title":"Mechanisms of early virologic failure in antiretroviral\u2013naive patients starting protease inhibitor-containing regimens: the APROVIR study","volume":"186","author":"Masquelier","year":"2002","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.11.003_bib10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1086\/380509","article-title":"Incidence of resistance in a double blind study comparing lopinavir\/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine","volume":"189","author":"Kempf","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.11.003_bib11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1086\/324354","article-title":"Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients","volume":"34","author":"Le Moing","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.11.003_bib12","series-title":"Rapport 2006. Prise en charge m\u00e9dicale des personnes infect\u00e9es par le VIH. Recommandations du groupe d\u2019experts","first-page":"37","article-title":"Traitement antir\u00e9troviral","author":"Yeni","year":"2006"}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X06003520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X06003520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:02:27Z","timestamp":1759971747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X06003520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S0399077X06003520"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2006.11.003","relation":{},"ISSN":["0399-077X"],"issn-type":[{"type":"print","value":"0399-077X"}],"subject":[],"published":{"date-parts":[[2007,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lopinavir\/ritonavir chez\u00a0le\u00a0patient infect\u00e9 par\u00a0le\u00a0VIH en\u00a0situation d'\u00e9chec virologique prolong\u00e9: \u00e9volution immunovirologique et\u00a0tol\u00e9rance chez\u00a0121\u00a0patients de\u00a0la\u00a0cohorte ANRS CO8 Aproco-Copilote","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2006.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}